[Meningeal gliomatosis--clinical features and results of treatment].
Fifteen (15.6%) patients of 97 with malignant glioma developed meningeal gliomatosis during at least 2 years after the initial treatment. The time between the first surgery and diagnosis of meningeal gliomatosis was less than 1 year in 10 cases, 1 to 2 years in 2 and over 2 years in 2. In the younger age group less than 20 years, the incidence of meningeal gliomatosis was higher (46%) than that (12%) in the older group. Despite intrathecal chemotherapy (cytosine arabinoside, bleomycin and methotrexate), all patients died 2 to 24 weeks after the diagnosis of meningeal gliomatosis. Experimental studies suggest that intrathecal ACNU may be promising for the treatment of meningeal gliomatosis.
Arita
N
N
Dept. of Neurosurgery, Osaka Univ. Med. School.
Hayakawa
T
T
Mogami
H
H
Ushio
Y
Y
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000473:pathology*; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000453:epidemiology / Q000556:secondary*; D006801:Humans; D015994:Incidence; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000556:secondary*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged
D003561:Cytarabine; D001761:Bleomycin; D008727:Methotrexate